Latest Infliximab Stories
SEOUL, Korea, May 25, 2011 /PRNewswire/ -- New findings presented from pooled analyses of the STELARAÂ® (ustekinumab) psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.
ABBOTT PARK, Ill., May 10, 2011 /PRNewswire/ -- Abbott's (NYSE: ABT) HUMIRAÂ® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis.
CHICAGO, May 9, 2011 /PRNewswire/ -- Data from a Phase 3 randomized, multicenter, open-label study demonstrated clinical response with REMICADEÂ® (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC), and showed a safety profile consistent with previous clinical trials conducted in an adult population.
CHICAGO, May 9, 2011 /PRNewswire/ -- New study findings showed that treatment with STELARAÂ® (ustekinumab) induced and maintained clinical response in patients with moderate to severe Crohn's disease who had previously failed or were intolerant to at least one tumor necrosis factor (TNF) antagonist.
Speaking at the UK National Stem Cell Network annual science meeting later today (30 March), Professor Miguel Forte will describe research into a new cell therapy for chronic inflammatory conditions such as Crohn's disease.
The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis.
Pfizer said on Friday that its rheumatoid arthritis drug met the main goals of a late-stage clinical trial.
ATLANTA and PORTLAND, Ore., March 2, 2011 /PRNewswire-USNewswire/ -- Two leading patient advocacy organizations have joined forces to educate people about psoriatic arthritis, an inflammatory disease that can lead to joint damage, especially if not diagnosed and treated early.
SAN DIEGO, March 1, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development progress for the year ended December 31, 2010. "Prometheus had another record year in 2010, our 14th consecutive year of sales growth," said Joseph M.
LONDON and MOUNTAIN VIEW, Calif., Jan. 12, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) and ChemoCentryx, Inc.
- a meat pie that is usually eaten at Christmas in Quebec